APA (7th ed.) Citation

R, C., D, R., JS, T., JJ, N., & R, H. (2024). Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: An analysis across TKI generations. Discover oncology, 15(1), 689. https://doi.org/10.1007/s12672-024-01606-9

Chicago Style (17th ed.) Citation

R, Cooper, Ramaswami D, Thomas JS, Nieva JJ, and Hsu R. "Assessing the Predictive Role of Platelet-lymphocyte Ratio in EGFR-mutated Non-small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Analysis Across TKI Generations." Discover Oncology 15, no. 1 (2024): 689. https://doi.org/10.1007/s12672-024-01606-9.

MLA (9th ed.) Citation

R, Cooper, et al. "Assessing the Predictive Role of Platelet-lymphocyte Ratio in EGFR-mutated Non-small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Analysis Across TKI Generations." Discover Oncology, vol. 15, no. 1, 2024, p. 689, https://doi.org/10.1007/s12672-024-01606-9.